To Top


Gastroenterology is the 3rd largest therapy area which contributes 10% of the Indian Pharmaceutical Market (IPM) value. With the changes in lifestyle and VUCA (Volatile, Uncertain, Complex, Ambiguous) environment, the therapy area is set to grow significantly in the upcoming 10 years.

Alkem has always believed to evolve as per the need of the therapy and currently, Alkem holds 7% of the total revenue generated by this TA.

At present, Alkem is the 3rd largest company in the GI Therapy Area (TA) of IPM. Alkem has built its trust by developing several products for GI disorders like GERD, gastric ulcers, anti-emetic, constipation, hyperacidity, diarrhea, worm infestation, etc.

Some of the highlights of Alkem’s Gastroenterology portfolio are

  • PAN is the No.1 ranked brand in sales value in PPI market*
  • Extending treatment options in Refractory GERD with a new launch PAN 80.
  • PAN-D is the No.1 ranked brand in sales value in PP I+ Domperidone market*
  • Obetohep is the No.1 ranked brand in sales value in Obeticholic acid market*
  • Ondem is the most preferred antiemetic and has been maintaining its leadership position in the respective segment.
  • Emty is the 3rd largest value brand in the Lactulose market*
  • Rifakem, an intelligent gut antibiotic is focusing on infectious diarrhea/IBS-D.
  • Noworm, a brand of Albendazole, is holding the 2nd position in the respective market.

* MAT March 2022